Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,729Revenue $M13.4Net Margin (%)-1,898.5Z-Score56.4
Enterprise Value $M2,241EPS $-3.4Operating Margin %-1,899.1F-Score2
P/E(ttm))0Cash Flow Per Share $-1.4Pre-tax Margin (%)-1,897.4Higher ROA y-yN
Price/Book5.310-y EBITDA Growth Rate %0Quick Ratio21.7Cash flow > EarningsY
Price/Sales3025-y EBITDA Growth Rate %0Current Ratio21.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-30.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-32.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M33.2ROI % (ttm)-27.3Gross Margin Increase y-yN

Gurus Latest Trades with GEVA

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GEVAGeorge Soros 2013-12-31 Sold Out -0.01%$45.51 - $69.69
($59.17)
$ 82.1639%Sold Out0
GEVAGeorge Soros 2013-09-30 Buy 0.01%$43.26 - $62.55
($49.11)
$ 82.1667%New holding, 17700 sh.17,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GEVA is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GEVA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOESS CARSTENSVP, CFO 2014-10-30Sell25,404$80.1-0.29 view
Goldberg Mark AlanEVP, Medical & Reg. Strategy 2014-09-19Sell790$65.2422.42 view
Goldberg Mark AlanEVP, Medical & Reg. Strategy 2014-09-17Sell13,579$65.0322.82 view
Quinn AnthonyEVP, CMO & Head of R&D 2014-09-02Sell10,000$70.1413.87 view
Williams GlenSVP, Technical Operations 2014-06-25Sell700$108.02-26.06 view
Quart Barry DDirector 2014-06-20Sell1,375$100-20.13 view
Quart Barry DDirector 2014-06-17Sell1,000$90-11.26 view
Quart Barry DDirector 2014-06-12Sell1,000$83.31-4.13 view
Goldberg Mark AlanEVP, Medical & Reg. Strategy 2014-06-11Sell21,597$80-0.16 view
BOESS CARSTENSVP, CFO 2014-05-16Sell9,927$81.94-2.53 view

Press Releases about GEVA :

    Quarterly/Annual Reports about GEVA:

    News about GEVA:

    Articles On GuruFocus.com

    More From Other Websites
    Synageva BioPharma (GEVA): Strong Industry, Solid Earnings Estimate Revisions Nov 25 2014
    Synageva Up on New Phase III Data on Sebelipase Alfa Nov 14 2014
    Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults... Nov 10 2014
    Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults... Nov 10 2014
    SYNAGEVA BIOPHARMA CORP Financials Nov 06 2014
    10-Q for Synageva BioPharma Corp. Nov 01 2014
    Synageva BioPharma beats 3Q profit forecasts Oct 31 2014
    Synageva BioPharma beats 3Q profit forecasts Oct 31 2014
    Synageva BioPharma Reports Third Quarter 2014 Financial Results Oct 30 2014
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
    Synageva BioPharma Reports Third Quarter 2014 Financial Results Oct 30 2014
    Synageva BioPharma to Present at the Nomura Biotechnology Conference Oct 29 2014
    Synageva BioPharma to Present at the Nomura Biotechnology Conference Oct 29 2014
    Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting Oct 23 2014
    Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting Oct 23 2014
    Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For... Oct 21 2014
    Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For... Oct 21 2014
    Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For... Oct 21 2014
    Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Oct 16 2014
    Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral... Oct 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK